BK polyomavirus microRNA levels in exosomes are modulated by non-coding control region activity and down-regulate viral replication when delivered to non-infected cells prior to infection by F. Martelli et al.
viruses
Article
BK Polyomavirus MicroRNA Levels in Exosomes Are
Modulated by Non-Coding Control Region Activity
and Down-Regulate Viral Replication When
Delivered to Non-Infected Cells Prior to Infection
Francesco Martelli 1, Zongsong Wu 2 ID , Serena Delbue 3, Fabian H. Weissbach 2 ID ,
Maria Chiara Giulioli 1, Pasquale Ferrante 3, Hans H. Hirsch 2,4,*,†
and Simone Giannecchini 1,*,† ID
1 Department of Experimental and Clinical Medicine, University of Florence, I-50134 Florence, Italy;
martelli.francesco85@gmail.com (F.M.); maria.chiara2591@gmail.com (M.C.G.)
2 Transplantation & Clinical Virology, Department Biomedicine (Haus Petersplatz), University of Basel,
CH-4003 Basel, Switzerland; zongsong.wu@unibas.ch (Z.W.); fabian.weissbach@unibas.ch (F.H.W.)
3 Department of Biomedical, Surgical and Dental Sciences, University of Milan, I-20100 Milano, Italy;
serena.delbue@unimi.it (S.D.); pasquale.ferrante@unimi.it (P.F.)
4 Infectious Diseases & Hospital Epidemiology, University Hospital Basel, CH-4003 Basel, Switzerland
* Correspondence: hans.hirsch@unibas.ch (H.H.H.); simone.giannecchini@unifi.it (S.G.)
† Both authors contributed equally to this study.
Received: 30 May 2018; Accepted: 29 August 2018; Published: 30 August 2018


Abstract: In immunosuppressed patients, BKPyV-variants emerge carrying rearranged non-coding
control-regions (rr-NCCRs) that increase early viral gene region (EVGR) expression and replication
capacity. BKPyV also encodes microRNAs, which have been reported to downregulate EVGR-encoded
large T-antigen transcripts, to decrease viral replication in infected cells and to be secreted in exosomes.
To investigate the interplay of NCCR and microRNAs, we compared archetype- and rr-NCCR-BKPyV
infection in cell culture. We found that laboratory and clinical rr-NCCR-BKPyV-strains show higher
replication rates but significantly lower microRNA levels than archetype virus intracellularly and
in exosomes. To investigate whether rr-NCCR or increased EVGR activity modulated microRNA
levels, we examined the (sp1-4)NCCR-BKPyV, which has an archetype NCCR-architecture but shows
increased EVGR expression due to point mutations inactivating one Sp1 binding site. We found
that microRNA levels following (sp1-4)NCCR-BKPyV infection were as low as in rr-NCCR-variants.
Thus, NCCR rearrangements are not required for lower miRNA levels. Accordingly, Sp1 siRNA
knock-down decreased microRNA levels in archetype BKPyV infection but had no effect on
(sp1-4)- or rr-NCCR-BKPyV. However, rr-NCCR-BKPyV replication was downregulated by exosome
preparations carrying BKPyV-microRNA prior to infection. To explore the potential relevance in
humans, urine samples from 12 natalizumab-treated multiple sclerosis patients were analysed.
In 7 patients, rr-NCCR-BKPyV were detected showing high urine BKPyV loads but low microRNAs
levels, whereas the opposite was seen in 5 patients with archetype BKPyV. We discuss the results
in a dynamic model of BKPyV replication according to NCCR activity and exosome regulation,
which integrates immune selection pressure, spread to new host cells and rr-NCCR emergence.
Keywords: polyomavirus; non-coding control region; microRNA; exosomes; persistence;
immunosuppression; BK virus
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1. Introduction
BK polyomavirus (BKPyV) is one of more than 10 human polyomaviruses (HPyV) and it infects
>90% of the general human population without ill effects [1–3]. BKPyV causes nephropathy or
haemorrhagic cystitis in immunocompromised patients, particularly after kidney or allogeneic
hematopoietic cell transplantation [4,5]. Seroprevalence data indicate that BKPyV transmission
occurs in early childhood [6] via the oral or respiratory route [7]. Subsequently, BKPyV reaches the
renourinary tract, presumably by primary viremia [7], where the virus establishes a latent infection [8].
Asymptomatic low-level BKPyV shedding has been demonstrated in 10% of BKPyV IgG-seropositive
healthy blood donors [9] providing evidence of immune escape in adult immunocompetent hosts.
Antibody levels decline during adult life [9,10] unless significant re-exposure occurs which includes
immunocompromised patients [11–14]. In immunocompromised individuals, however, urinary BKPyV
shedding is more frequent, often with urine viral loads of exceeding 7 log10 copies/mL that become
apparent as “decoy cell” shedding [2,15–18]. In kidney transplant or allogeneic hematopoietic cell
transplant patients, high-level BKPyV replication precedes nephropathy or haemorrhagic cystitis,
respectively [4,5]. Increased BKPyV reactivation rates have also been observed in other solid organ
transplant recipients and in HIV/AIDS patients [19–21]. However, the molecular details of regulating
BKPyV replication in immunocompetent individuals and the relevance for disease progression are not
well understood.
BKPyV has a double-stranded DNA genome of approximately 5 kb, which can be divided into:
(i) the early viral gene region (EVGR) encoding the small and the large T-antigen; (ii) the late viral gene
region (LVGR) encoding the capsid proteins Vp1, Vp2, Vp3, agnoprotein and microRNAs; and (iii) the
non-coding control region (NCCR) [2,22]. The NCCR harbours the origin of genome replication ori and
promoter/enhancer with DNA-binding sites for transcription factors mediating the secondary host
cell specificity [23], as well as the timing and course of EVGR-expression, viral DNA-replication and
LVGR-expression [2].
BKPyV sequences commonly found in the urine of healthy persons have an archetype NCCR
architecture of sequence blocks arbitrarily denoted O-P-Q-R-S [2,9]. In immunocompromised patients
with BKPyV-disease, viral variants with rearranged NCCR (rr-NCCR) architecture have been shown to
emerge as majority species and are associated with disease severity [24]. In these patients, archetype
NCCR-BKPyV is still found in urine but molecular cloning has demonstrated the presence of a viral
quasi-species with co-existing rr-NCCR minority species [25], which may be an indicator of imminent
pathology [26]. In vitro studies and in vivo observations support the view that rr-NCCRs confer
a higher replicative activity in vitro but which depends on the lack of cellular immune functions
in vivo [24]. A similar link between rr-NCCR and disease was also observed for JCPyV in HIV/AIDS
patients with progressive multifocal leukoencephalopathy [27,28], or for HPyV-7 and HPyV-9 [23].
Together, the data suggest that HPyV-NCCR rearrangements arising in immunocompromised patients
are not only a surrogate marker of long-standing immunologically uncontrolled replication but also
represent a virulence determinant of activated EVGR expression and increased replication capacity
causing disease.
Given the complex diversity of NCCR rearrangements that affect various transcription factor
binding sites as well as the overall architecture, a systematic study of inactivating specific transcription
factor binding sites by point mutation was conducted, which maintained the linear archetype
architecture of BKPyV-NCCR [29]. Of note, mutations inactivating the Sp1 site located proximal
to the LVGR promoter termed SP1-4 resulted in a phenotype functionally equivalent to NCCR
rearrangements (group 1) and which had been identified in patients with BKPyV disease [29].
Intriguingly, a similar, albeit low-affinity Sp1 binding site SP1-2 has been located upstream of the
EVGR promoter, the inactivation of which (e.g., sp1-2) decreased EVGR expression and replication
(group 3) [29]. Further mutational dissection of the BKPyV-NCCR as well as electrophoretic mobility
shift assays and chromatin immunoprecipitation analysis revealed that EVGR-expression involves
a classic inducible TATA-box promoter. Upstream, the EVGR promoter partially overlaps with a
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constitutive housekeeping gene-type LVGR promoter using a TATA-like box in the opposite orientation,
in which a high-affinity SP1-4 sites acts as a central switch of bidirectional gene expression [30].
sp1-4 point mutations inactivating Sp1 binding cause constitutive activation of EVGR expression and
increased viral replication without NCCR rearrangements [30].
Besides the NCCR, another layer of regulating EVGR expression has been described at the
posttranscriptional level mediated by microRNAs (miRNAs) miRNA-B1-3p and miRNA-B1-5p
encoded in the distal LVGR [22,31–33]. Similar to other PyVs [31,33–35], BKPyV miRNAs are
short noncoding RNAs, which target large T-antigen transcripts and thereby down-regulate viral
replication [32,36,37]. This posttranscriptional safeguard has been implicated in the escape from large
T-antigen-specific cytotoxic T-cells [34], which have recently been linked to the effective curtailing
of BKPyV replication in kidney transplant patients [38,39]. The regulation of miRNAs expression is
subject of ongoing studies, which may involve sequences close to the miRNA gene as well as the
NCCR [22,40,41]. Moreover, miRNAs of BKPyV and the closely related JCPyV miRNAs have been
detected in blood, urine and cerebrospinal fluid samples, often together with the corresponding viral
loads with few cases reporting the nature of the NCCR structures [42,43]. It has been suggested that
urinary exosomes associated BKPyV-miRNA may be a surrogate marker for BKPyV pathology [44].
Thus, the association between miRNAs and exosomes has also raised questions about their regulatory
potential in non-infected neighbouring cells [43,45,46].
Since the NCCR and the miRNA represent two different, formally independent modalities of
regulating BKPyV replication at the transcriptional and post-transcriptional level, respectively, we
examined the interplay of NCCR architecture and miRNAs expression following BKPyV infection.
Imperiale and colleagues reported that BKPyV miRNA levels were low following infection with
laboratory strains carrying rr-NCCR. In a first step, we therefore compared miRNA levels in archetype
and different laboratory- and patient-derived rr-NCCR-BKPyV variants in cell culture. We also
examined the miRNA levels seen with the (sp1-4)NCCR-BKPyV and (sp1-2)NCCR-BKPyV, which,
as outlined above, have an archetype architecture but show increased and decreased EVGR expression
and viral replication, respectively. The role of Sp1 was further evaluated by siRNA-SP1 known-down.
To investigate whether or not rr-NCCR-BKPyV replication could still be down-regulated by mircoRNA,
we transferred exosomes carrying BKPyV-microRNA cargo onto uninfected cells prior to infection.
Finally, we explore the potential relationship of BKPyV load, NCCR architecture and miRNA levels
in vivo in urines from multiple sclerosis patients treated with natalizumab. We then attempt to
integrate the results in a dynamic model of transcriptional and posttranscriptional regulation and
discuss the potential implications in immunocompetent and immunosuppressed hosts, favouring
archetype and rearranged NCCR-BKPyV, respectively.
2. Materials and Methods
2.1. Urine Sampling
The urine samples used in this study were obtained from 12 relapsing-remitting multiple sclerosis
patients undergoing intravenous natalizumab treatment at the Multiple Sclerosis Center, Neurological
Institute Mondino, Pavia, and had enrolled for a previous study [47]. None of them developed
symptoms or signs of polyomavirus-associated diseases at presentation or during the follow-up.
The study was approved by the local institutional review board, “Fondazione Istituto Neurologico
Mondino”, Pavia, Italy (n. 101MS326). Human samples were taken after obtaining the informed
consent from the patients or control subjects in accordance with the tenets of the Declaration of Helsinki.
2.2. Cell Cultures and BkPyV Molecular Clones
African green monkey kidney, SV40-transformed Cos-7 cells line (CRL1651, ATCC, Manassas,
VA, USA [48]) were grown in Dulbecco modified Eagle’s medium (DMEM) supplemented with 10%
foetal bovine serum (FBS, SIGMA, Milan, Italy). Primary human renal proximal tubule epithelial
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cells (RPTECs, PCS-400-010, ATCC, Manassas, VA, USA) were grown in an epithelial cell medium
supplemented with epithelial cell growth supplement and 2% FBS (ScienceCell Research Laboratory,
Carlsbad, CA, USA). BKPyV strains were derived from molecular clones carrying archetype NCCR
(clone WW1.4) [24], a rr-NCCR laboratory strain (Dunlop, Akron, OH, USA) [49], clinical rr-NCCR
variants having deletions in the Q- and the R-block (clone del5.3, del15.10) [24,29] and the archetype
NCCR variants carrying point mutations of Sp1 binding sites in the Q-block (clone sp1-4) or in the
P-block (clone sp1-2) [29,30].
2.3. BKPyV Infection of Cos-7 and RPTECs
Transfection of BKPyV genomic DNA into Cos-7 cells was performed at 90–95% confluence
in 6-well plates using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. At 6 h posttransfection, the medium was replaced by DMEM containing
10% FBS. At 14 days posttransfection, Cos-7 cells were harvested by scraping off cells in 1/10 of the cell
culture supernatant. Virus was released by 3 cycles of freeze-thawing of the cells and centrifugation
at 800 g for 5 min. For the infection experiments, Cos-7 and RPTECs were seeded at 7.5 × 105 cells
and 3.12 × 105 cells per well in 6-well plate with 2 mL of DMEM (10% FBS) or supplemented
EpiCM medium (2% FBS). After 24 h at a confluence of approximately 70%, Cos-7 and RPTECs were
exposed to 500 microliters of the corresponding virus preparations (MOI 1) obtained from Cos-7 cells
after transfection at 37 ◦C for 2 h followed by removal and replacement with DMEM (10% FBS) or
supplemented EpiCM medium (0.5% FBS). Cells and supernatant were harvested at 12, 24, 48 and
72 h post infection. Titration revealed that approximately 5–10 × 106 genome copies of BKPyV-Dunlop
genomes on 50,000 RPTECs or Cos-7 cells at infection typically elicits a multiplicity of infection of 1
after 48 h according to fluorescent focus forming units using staining for large T-antigen; H.H. Hirsch
and M. Wernli, unpublished results and see References [50,51].
2.4. Plasmid Exosomes BKPyV miRNA Expression in Cos-7 Cells
BKPyV-miRNAs were inserted into the pcDNA 6.2GW/EmGFP-miR (Invitrogen,
Carlsbad, CA, USA) vectors and cloned according to the manufacturer’s instructions. To this
end, specific oligonucleotide pairs were designed on the BKPyV miRNA mature sequence
(5′TGCTGATCTGAGACTTGGGAAGAGCATTTTTGGCCACTGACTGAATGCTCTTCCCATCTCA
GAT3′ forward oligonucleotide and 5′CCTGATCTGAGATGGGAAGAGCATTCAGTCAGTGGCCAA
AAATGCTCTTCCCAAGTCTCAGATC3′ reverse oligonucleotide; BKPyV-miRNA mature sequence
is underlined below the sequences shown). Next, the corresponding expression vectors
pcDNA6-BK-miRNA (10 µg) were transfected into Cos-7 cells (7.5 × 105 cells per well in
6-well plate) using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). BKPyV-miRNA expression
vectors system (encodes for the green fluorescence protein GFP) efficiency was assessed at 24h
after transfection based on the number of GFP-positive cells, as determined by flow cytometry.
In subsequently experiments exosomes carrying BKPyV-miRNA were purified at 24 h, 48 h and 72 h
from transfected Cos-7 cells and were quantified. The sequence of the miRNA inserts was confirmed
by sequencing.
2.5. Exosome Enriched Vesicles Extraction
The exosome-enriched vesicles were isolated starting from 250 µL of cells supernatant collected by
prior centrifugation at 14,000 g for 20 min, using the exosome-specific extraction kit (Norgen, Thorold,
ON, Canada), following the manufacturer’s protocols. Characterization of the exosome-preparation
was done by demonstrating the presence of 112 nm vesicles present at a density of a mean total particles
concentration of 107/mL. Further characterization was achieved by western blot, detecting three
markers of exosome tetraspanin/CD63, CD81 and Annexin II (Supplement Figure S1). Before analysis,
exosome-enriched vesicles were treated with RNase and DNase to remove miRNA and DNA not
protected inside the exosomes.
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2.6. Exosome Addition and Anti BKPyV-miRNA Inhibition in Cos-7 Cells
Exosomes carrying BKPyV-miRNA (103 copies) were added to the Cos-7 cells (7.5 × 105 cells per
well in 6-well plate) and used to test the effect on subsequent viral infection. Where indicated,
the exosomes were added to Cos-7 cells in the absence or presence of inhibitory specific
antago-BK-miRNA-5p (Inh-BK-miRNA, a phosphorothioate oligonucleotide with the sequence
complementary to the BK-miRNA) synthetic molecule, which had been transfected into Cos-7 cells
using a 5 µM final concentration, together with lipofectamine 2000 (Life Technologies, Foster City,
CA, USA). Unrelated miRNA (Unrel-miRNA, a phosphorothioate oligonucleotide with an unrelated
sequence) synthetic molecule, was used as control.
2.7. BKPyV DNA Quantification
Viral DNA was extracted from 0.15 mL of urine, from 2 × 104 cells and cell supernatant
of tissue cultures with the High Pure PCR Template Preparation kit (Roche, Basel, Switzerland).
DNA extracted was subjected to quantitative real-time PCR (qPCR) assays using primer and probe
targeting Vp1 gene (BKVPf forward primer 5′-AGTGGATGGGCAGCCTATGTA-3′, BKVPr reverse
primer 5′-TCATATCTGGGTCCCCTGGA-3 and BKVPp TaqMan MGB probe labelled with VIC VIC-5′
AGGTAGAAGAGGTTAGGGTGTTTGATGGCACAG 3′) (Life Technologies, Foster City, CA, USA).
Each reaction was carried out with negative controls (no template) and DNA standards (diluted to
contain 101–106 copies per millilitre) of a plasmid containing the BKPyV molecular clone. The lowest
limit of detection of the assay was 10 copies per millilitre of urine and micrograms of total DNA [52].
2.8. BKPyV Pre-miRNA and Mature miRNA Quantification
Total RNA was isolated from 2.0 × 106 Cos-7 and RPTECs cells using the mirVana miRNA
isolation Kit (Ambion, Foster City, CA, USA), and from exosomes contained in 250 µL of cell-free
supernatant that had previously been centrifuged at 14,000 g for 20 min using an RNA exosome-specific
circulating extraction kit (Norgen). The miRNA expression was measured and quantified with a specific
pre-miRNA and mature bk-miRNA-5p quantitative stem-loop RT-PCR MiRNA assay whose primers
were designed on the specific region of the BKPyV WW clone (Life Technologies, Foster City, CA,
USA) according to the manufacturer’s protocol. Each reaction was performed in triplicate using 10 ng
of extracted RNA, including negative controls (no template) and synthesized oligonucleotides as
standards (diluted to contain 101–106 copies). The lowest detection limit of the assay was 10 copies/ng
of RNA. The assay was specific and reproducible, as demonstrated in preliminary experiments
using a BKPyV oligonucleotide standard (with <0.5 Ct value inter-assay variation) and observing no
amplification of unrelated oligonucleotide targets.
2.9. siRNA knock-Down of Sp1 and Immunoblotting
Cos-7 cells were transfected in a 6-well plate using per well 2 µg of siRNA targeting Sp1
(SP1-siRNA, Mission esiRNA SIGMA), or 2 µg of siRNA scrambled form (Scr-siRNA), or mock-treated
without siRNA added (mock). At 24 h post-transfection, Cos-7 cells were infected at multiplicity of
infection (MOI) of 1, using BKPyV-infectious supernatant obtained after transfection of Cos-7 cells.
BK-miRNA-5p expression in cells and presence in exosomes enriched vesicles were measured at
48 h post infection. Immunoblots were used to compare Sp1 expression and cytochrome P450 as
control. Briefly, cell extracts were prepared from Cos-7 cells at 48 h after transfection of SP1-siRNA,
Scr-siRNA and mock-treatment and 15 µg of extract were analysed by 10% SDS-PAGE, transferred
onto nitrocellulose membrane (BIO-RAD), block the membrane with 5% bovine serum albumin
and then incubated with the rabbit anti-Sp1 (PLA0044, SIGMA) and rabbit anti-cytochrome-P450
polyclonal antibody (PA1-343, SIGMA) followed by a peroxidase-conjugated anti-rabbit IgG antibody
(A0545, SIGMA).
Viruses 2018, 10, 466 6 of 21
2.10. NCCR Sequencing
A nested-PCR was used to obtain the NCCR product for sequencing. Briefly, 100 ng of total
DNA was amplified using two pairs of primers: first pair of primers, BKTT1 forward 5′ AAG
GTC CAT GAG CTC CAT GGA TTC TTC C 3′ and BKTT2 reverse 5′ CTA GGT CCC CCA AAA
GTG CTA GAG CAG C 3′, generating a 684 bp DNA fragment; the second pair of primers,
BK-1 forward 5′ GGCCTCAGAAAAAGCTTCCACACCCTTACTACTTGA 3′ and BK-2 reverse 5′
CTTGTCGTGACAGCTGGCGCAGAA 3′, that amplified a portion of the first amplicon generating
a fragment of 354 bp. The PCR products were purified using the PCR purification Kit (Qiagen,
Hilden, Germany) and sequenced using the BigDye Terminator Cycle-Sequencing Ready Reaction
(Applied Biosystems, Foster City, CA, USA). The sequences were analysed and edited using Bioedit
5.0.9 (Tom Hall of Ibis Therapeutics, Carlsbad, CA, USA).
2.11. Statistical Tests
The data were analysed using Student’s t-tests. p-values less than 0.05 were considered
statistically significant.
3. Results
3.1. Rearranged NCCR-BKPyV Variants Show Higher Viral Loads But 10-Fold Lower miRNA Expression than
Archetype NCCR BKPyV
To address the role of NCCR and microRNAs, we compared archetype and rearranged
NCCR-BKPyV in cell culture. Accordingly, cloned genomes of the archetype NCCR-BKPyV-WW(1.4)
and the laboratory stain BKPyV-Dunlop, which carries a rr-NCCR (Figure 1) were transfected into
Cos-7 cells and infectious supernatants were prepared. Following infection, BKPyV-loads rapidly
increased in Dunlop-infected cells but only slowly in archetype WW(1.4) infected cultures over 72h post
infection (Figure 2A; left top panel). As shown previously [24,50,53], only one viral replication cycle is
complete for the Dunlop strain under these conditions and only few secondary infection events have
started as evidenced by large T-antigen positive/Vp1-negative immunofluorescence. BKPyV miRNA
also increased during this time course but the levels seen in the archetype-infected cells (Figure 2A;
left middle panel) and in the corresponding exosome preparations (Figure 2A; left bottom panel) were
almost as high as in the Dunlop-infected cultures and therefore much higher than expected from the
replication kinetics and the available genome copy number in particular.
Direct comparison of the miRNA levels expressed per BKPyV genome copy number revealed
significantly higher expression in cells and in exosome preparations generated during archetype
BKPyV infection than observed for the rr-NCCR-Dunlop strain (Figure 2B; left panels).
Given the difference in NCCR architecture between archetype WW(1.4) and rearranged laboratory
Dunlop virus, we were interested to examine the patient-derived rr-NCCRs del(5.3) and del(15.10)
variants that had emerged in kidney transplant recipients and had been shown to increase EVGR
expression and replication rates in several previous studies [24,29]. The results demonstrated that both
of patient-derived rr-NCCR variants behaved similar to the Dunlop-strain showing high replication
levels and low miRNA expression in cells and exosome preparations (Figure 2A,B; right panels).
To investigate whether NCCR rearrangements or increased EVGR activity played a role in
modulating the miRNA levels, we examined the (sp1-4)NCCR-BKPyV, which has an archetype
architecture but shows increased EVGR expression and viral replication due to point mutations
inactivating the SP1-4 binding site upstream of the LVGR transcription start site [29,30] (Figure 1).
As a control, we chose the (sp1-2)NCCR-BKPyV, in which the SP1-2 site located upstream of the
EVGR transcription start site was inactivated by point mutations and which showed only low EVGR
expression and replication [29,30] (Figure 1). We observed high replication rates and low miRNA
expression in cells and exosome-preparations for the (sp1-4)NCCR-BKPyV, whereas the opposite was
true for (sp1-2)NCCR-BKPyV (Figure 2A,B; right panels). The results indicated lower miRNA expression
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was associated with increased EVGR expression and replication rates and that rearrangements of the
NCCR were not necessary for the observed reduction in miRNA levels.Viruses 2018, 10, x 7 of 21 
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Figure 1. Schematic representation of NCCR architecture and EVGR and LVGR expression pattern of
BKPyV strains. BKPyV NCCR architecture, Sp1 binding sites and expression levels are schematically
summarized for the archetype (WW1.4), the laboratory-derived rr-NCCR (Dunlop), isolates from kidney
transplant patients carrying rearranged NCCRs: BKPyV rr-NCCR del(5.3) and del(15.10) genome, as well
as the BKPyV archetype NCCR carrying point mutations inactivating Sp1 binding to LVGR-proximal
(sp1-4) and EVGR-proximal binding sites (sp1-2). Sp1 binding to the directional (non-palindromic)
sequences is indicated as yellow triangle, dashed-line triangles indicate point mutations. The sequence
blocks O, P, Q, R and S are indicated by coloured boxes and their respective length in base pairs in
subscripts. The relative expression levels of the EVGR and the LVGR is represented by the thickness of
the red and green arrows, whereby +++++, very strong; to + weak (see references [24,29,30]).
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BKPyV variants in cell culture. (A) Cos-7 cells were infected with the indicated strains (Figure 1) and 
viral load and BK-miRNA-5p expression were measured in cells and exosome preparations at 12, 24, 
48 and 72 h post infection. BKPyV genome load was expressed per total µg DNA; miRNA given per 
total ng RNA (mean ± standard deviation of 3 independent experiments). (B) Time course comparing 
of miRNA expression levels in cells or exosome preparations following infection with archetype or 
indicated NCCR variant strains as described in Figure 1. Results are expressed as BKPyV-miRNA 
Figure 2. Viral replication and miRNA levels of archetype and different laboratory- or patient-derived
BKPyV variants in cell culture. (A) Cos-7 cells were infected with the indicated strains (Figure 1) and
viral load and BK-miRNA-5p expression were measured in cells and exosome preparations at 12, 24,
48 and 72 h post infection. BKPyV genome load was expressed per total µg DNA; miRNA given per
total ng RNA (mean ± standard deviation of 3 independent experiments). (B) Time course comparing
of miRNA expression levels in cells or exosome preparations following infection with archetype or
indicated NCCR variant strains as described in Figure 1. Results are expressed as BKPyV-miRNA
relative levels to DNA genome copy number normalized to archetype WW(1.4) clone values obtained
at 12 h post-infection set to 1 (-fold; *, p < 0.05; ** p < 0.01).
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3.2. Sp1 Expression Levels Modulate BKPyV miRNA Levels in Archetype NCCR Virus And Variants With
Low EVGR Expression But Not in Viral Variants Having an Activated EVGR Expression
Since the bi-directional expression of the archetype NCCR is critically modulated by Sp1 binding
sites with high (SP1-4) and low affinity (SP1-2) binding sites in the EVGR and LVGR promoter,
respectively [29,30], we wondered if knock-down of Sp1 had any influence on miRNA expression
levels. Accordingly, Cos-7 cells were transfected with siRNA targeting SP1, with scrambled siRNA,
or only mock-treated and miRNA expression levels were analysed after infection with archetype,
the two point-mutant derivatives sp1-2 and sp1-4; and the Dunlop strain (Figure 1).
Sp1 knock-down was verified by immunoblotting demonstrating a significant reduction in the
siRNA-SP1- but not in the scrambled siRNA- or the mock-treated control cells (Figure 3; top panel).
In the mock and scrambled siRNA controls, the original observation was confirmed showing high levels
of BKPyV-miRNA following archetype- and (sp1-2)NCCR-BKPyV infection, whereas low levels were
seen following (sp1-4)NCCR-BKPyV and Dunlop infection, both in cells and corresponding exosome
preparations (Figure 3; blue and green bars). In the siRNA-SP1 treated cells, no change was seen in
BKPyV-miRNA levels in Dunlop- or (sp1-4)NCCR-BKPyV-infected cells, whereas a significant reduction
was seen in archetype and (sp1-2)NCCR-BKPyV-infected cells (Figure 3; red bars). The results indicated
that knock-down of Sp1 protein by siRNA was associated with a significant reduction in cellular and
exosomal miRNA levels in BKPyV strains having an intact SP1-4 binding site, whereas there was
little change in cells infected with virus strains showing constitutively activated EVGR expression.
Thus, Sp1 availability for binding on the SP1-4 site appeared to play a key role in BKPyV-miRNA
expression levels.
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Figure 3. Effect of Sp1 knock-down on BKPyV miRNA-5p expression. Cos-7 cells were transfected
with SP1-siRNA, scra bled Scr-siRNA or ock-treated and at 24 h posttransfection, infected with
the indicated viral strains. Top panel sho s the i unoblot of Sp1 and cytochro e P450 protein
levels at 48 h post-transfection as described in aterials ethods. iddle and lo er panel sho s
the B - iR -5p expression easured in cells and in exoso e preparations at 48 h post infection,
respectively. The values result from 3 independent experiments ( ean ± standard deviation; Student’s
t test, ** p < 0.01).
3.3. BKPyV miRNA Levels in Primary Human Renal Tubular Epithelial Cells (RPTECs) Inversely Correlate
it t e r- cti it a e licatio ate of rc et e a rr- - iruses
t t s st i s t s, t t r l t r t f i f ti i t st,
t s lls ere infected with archetype W(1.4)-, (sp1-4)- and Dunlop strai s and BKPyV-DNA
load and miRNA-5 xpression was measured at 1 , 24, 48 and 72 h st-i f ti . s s ri
r i sl [ ], - l t i t t t s - r li t si ifi tl f st r t t
rc t - (1.4) but there as little ifference in i er t t l i c lls r s
r r ti s ( i r ). r, t - i - l ls r ir l r si ific tl
i r i t rc t -i f ct s s s t i t c rr s i r r ti s
f ll i l r (s - )-i f cti ( i r ).
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miRNA-5p expression in RPTECs and corresponding exosome- preparations. RPTECs were infected
and viral DNA genome and BKPyV-miRNA-5p expression were measured at 12, 24, 48 and 72 h post
infection as detailed in Materials & Methods. BKPyV genome load was expressed per total µg DNA;
miRNA was quantified per total ng RNA (mean ± standard deviation of 3 independent experiments).
(B) Comparison of relative miRNA expression levels per BKPyV genome copy (template) in cells.
Results are expressed as BKPyV-miRNA levels normalized to BKPyV genome copy number, archetype
WW(1.4) values at 12 h post-infection are set to 1 (-fold; * p < 0.05; ** p < 0.01).
To address the question, whether or not the differences in mature BKPyV-miRNA-5p were related
to the expression levels of the miRNA gene r differenc s in maturation or degradation, we examined
the amount of precursor miRNA (pre-miRNA) which onsists of the 5′- and 3′-miRNA linked by a
hairpin loop in RPTEC (Figure 5). Th results indicated that the BKPyV pre-miRNA levels behaved
sim lar to what has been observed for the mature BKPyV-miRNA-5p, namely being high in archetyp
virus but lo in t e variants (Dunlop and sp1-4 mutant) hav ng increased EVGR activ ty.
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representation of the BKPyV pre-miRNA hairpin and the corresponding BKPyV-miRNA-5p and
miRNA-3p sequence (underlined). (B) Time course of BKPyV pre-miRNA expression levels after
infection of RPTECs with the indicated strains. Mean values ± standard deviation of 3 independent
experiments are shown. (C) Comparison of relative BKPyV pre-miRNA expression levels per BKPyV
genome copy (template) in cells. Results are expressed as BKPyV-miRNA levels normalized to BKPyV
genome copy number, archetype WW(1.4) values at 12 h post-infection are set to 1 (-fold; ** p < 0.01).
3.4. Pre-Infection Addition of BKPyV-Exosome Preparations Containing BKPyV miRNA Inhibit BKPyV
Replication of Dunlop or sp1-4 Mutant But Have No Effect On Archetype BKPyV or sp1-2 Muta t Strains
Given the rapid replication of BKPyV-variants with activated EVGR expression having only
low levels of BKPyV-miRNA per gen me template, we wondered if rr-NCCR-BKPyV replicati
could still be down-regulated by miRNA. To this end, e transferre exosome preparations carrying
BKPyV-microRNA cargo onto uninfected cells prior to BKPyV infection. To avoid potential interference
or confounding factors associated with exosome preparations from B PyV-infected cells, we prepared
exosomes from Cos-7 cells transfected with the plasmid vector pcDNA6-BK-miRNA expressing
BKPyV miRNA-5p and the pcDNA6-miRNA vector expressing an unrelated miRNA-5p as control
(see Materials & Methods).
The time course up to 72 h post-transfection showed increasing BKPyV-miRNA-5p levels in
cells and in corresponding exosome reparations (Figure 6A). Exosome uptake and internalization
after ad ition on Cos-7 cells was verified by the positive fusion assay performed based on
octadecyl-rhodamine lipid probe dequenching as previously described (Supplement Figure S2).
The amount of detectable BKPyV-miRNA-5p after exosome addition did not change p to 72 h
post-addition, whereas no BKPyV-miRNA was detected when using exosomes from control-transfected
cells (Figure 6B).
We next tested the effect of exosome preparation on subsequent viral infection. The results indicate
that replication of the BKPyV-Dunlop and the point mutant (sp1-4)-NCCR-BKPyV was significantly
inhibited, if infection was performed after addition of exosomes prepared fro BKPyV-miRNA-5p
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transfected cells. Instead, exosomes prepared from cells transfected with an unrelated miRNA
expression vector or from untransfected cells (mock) had no effect (Figure 6C; top panels). Under these
conditions, archetype BKPyV and the (sp1-2)-point mutant replicated slowly but without significant
inhibition by exogenous exosome addition. Of note, no inhibition of BKPyV-Dunlop or sp1-4 mutant
replication was observed, when exosome preparations carrying BKPyV-miRNA-5p and a specific
antago-BK-miRNA (Inh-BK-miRNA) molecules, whereas unrelated synthetic miRNA (Unrel-miRNA)
had no effect (Figure 6D; bottom panels).
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not archetype or (sp1-2) BKPyV replication. (A) Cos-7 cells were transfected with pcDNA6-BK- miRNA
(pcD-BK-miRNA). Then, BK-miRNA expression in Cos-7 cells and in exosomes enriched vesicles
derived from supernatant was measured after indicated time post transfection. (B) Detection of
BKPyV-miRNA-5p in Cos-7 cells after addition of exosome preparations from pcDNA6-BK-miRNA-5p
and control transfected or mock-treated cells. (C) BKPyV loads after exosome addition prepared
from cells transfected with the indicated expression vectors (Exo-BK-miRNA, unrelated miRNA,
or mock), or after direct transfection of the pcDNA6-BK-miRNA expression vector (see flow-chart).
(D) BKPyV loads after exosome addition prepared from cells transfected with the indicated expression
vectors (Exo-BK-miRNA, unrelated miRNA, in the presence or absence of a specific antago BK-miRNA
called Inh-BK-miRNA), or after direct transfection of the pcDNA6-BK-miRNA expression vector
(see flow-chart). The corresponding exosome preparations are indicated according to the transfection
vector (e.g., BKPyV-miRNA-5p; unrelated miRNA; mock; in the presence of Inh-BK-miRNA,
a synthetic phosphoro-thioate oligonucleotide with the sequence complementary to the BK-miRNA or
a corresponding unrelated miRNA. The values represent the mean ± standard, ** p < 0.01.
3.5. Analysis of the BKPyV NCCR Architecture and Exosomes Content in Urine Samples of
Immunocompromised Patients
To explore the potential relevance in humans, urine samples from 12 natalizumab-treated multiple
sclerosis patients were analysed. Twelve out of 25 BKPyV-DNA positive patients were identified among
42 natalizumab-treated multiple sclerosis patients enrolled in previous study [47]. The sequencing of
the BKPyV NCCRs identified the presence of predominantly rr-NCCR in the urine samples collected
from 7 patients, subjected to long term natalizumab treatment. Archetype NCCR BKPyV strains were
detected in the urine samples from the remaining 5 patients. Overall, the urine BKPyV load in patients
with predominantly rr-NCCR BKPyV was higher than in patients with archetype BKPyV. The opposite
was true for BKPyV miRNA-5p expression levels, being low in the 7 patients carrying rr-NCCR variants
and in the 5 patients shedding archetype NCCR BKPyV (Figure 7).
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time at which NCCR sequence was obtained from urine samples. Panels on the left show the results
obtained for 5 patients with BKPyV carrying archetype NCCRs (patient ID 1a–5a); Panels on right show
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4. Discussion
The regulation of BKPyV persistence and reactivation is receiving increasing attention [8] in the
light of the almost universal but well controlled BKPyV infection of the general human population and
the increasing BKPyV diseases in patients under potent immunosuppressive regimens [4,5,54,55]. So far,
two major mechanisms of regulating BKPyV replication have emerged, which involve transcriptional,
NCCR-based and post-transcriptional miRNA-based mechanisms targeting EVGR expression [24,41].
Pioneering work from Imperiale and co-workers has demonstrated that both layers of regulation
appear to interact since low BKPyV miRNA-5p levels were seen in infection by rapidly replicating
BKPyV carrying rr-NCCRs, whereas high miRNA-5p levels were seen in archetype BKPyV [41].
In this study, we extend these observations from laboratory strains to patient-derived isolates and
show that BKPyV miRNA-5p levels are decreased following infection of patient BKPyV carrying diverse
NCCR rearrangements (Figure 1). Moreover, we demonstrate that point mutations inactivating a single
Sp1 binding site (sp1-4) in an otherwise archetype NCCR have a similar effect. This (sp1-4)-mutation
has been shown to confer a phenotype of increased EVGR expression and more rapid viral replication
(group 1) similar to rr-NCCR BKPyV variants [29]. Thus, our results indicate that NCCR rearrangements
are not required for the lowered miRNA levels but suggest that the activation of EVGR expression
is important. The latter was supported by another Sp1 point mutant (sp1-2) showing which
permits only modest EVGR expression, while LVGR expression is also reduced (group 3) [29]
and which showed high-levels of BKPyV miRNA similar to the archetype WW(1.4)-NCCR-BKPyV.
Of note, the BKPyV miRNA-5p expression of archetype and (sp1-2)-mutated NCCR-BKPyV could
be significantly diminished by reduced Sp1 levels following siRNA-SP1 knock-down. Conversely,
variants carrying rearranged or (sp1-4)-mutated NCCRs were not affected. Parallel experiments in
human RPTECs generated similar results, suggesting that the observations were also relevant in the
human situation. The data support the notion that BKPyV miRNA-5p levels and the NCCR activity
are critically linked by Sp1 binding to the SP1-4 site. Independently, a principle role of Sp1 for BKPyV
replication has recently emerged from a genome-wide interference study [56].
While our study provides a detailed accounting of the inverse association of EVGR activity and
miRNA-5p expression, the exact molecular mechanisms need to be addressed further. Inverting
the orientation of the rr-NCCR has been shown to confer high LVGR expression at the expense
of EVGR [23,24] and corresponding recombinant viruses show increased miRNA expression [41].
Whether such LVGR transcription opens the access to the miRNA promoter region, provides
transcription factors and enzymatic complexes, or extended transcripts is presently discussed.
Conversely, activated EVGR transcription might simply outcompete the available miRNA transcripts,
or confer resistance to downregulation by another as yet unknown mechanism including antisense
stealth transcripts or processing from pre-miRNA to miRNA. In our study, we observed that BKPyV
pre-miRNA were similarly affected by the NCCR activity as the mature miRNA-5p suggesting
that transcript generation rather than miRNA processing, maturation or degradation was affected.
No evidence for a difference in cellular miRNA by packaging and secretion as exosomes was obtained,
since both cellular and exosomal levels mirror-imaged the activity of the NCCR in both compartments.
The possibility that BKPyV miRNAs were no longer able to downregulate replication of variants
with activated EVGR was refuted in time course experiments adding BKPyV-miRNA-5p loaded
exosome preparations to host cells prior to infection, which demonstrated a significant reduction of
the BKPyV-Dunlop and the (sp1-4)-point mutant. This interpretation was supported by inclusion of an
antagonist synthetic phosphorothioate oligonucleotide reversing replication inhibition.
The polyomavirus miRNA-5p has been proposed to act as an important safeguard silencing
residual large-T-antigen expression of the archetype BKPyV during viral persistence [34,41]. Efficient
transcriptional and posttranscriptional synergy in downregulation of large T-antigen expression may
permit escape from cytotoxic CD8 T-cell effectors, which we have been shown to preferentially
target T-antigen epitopes [38,39]. Conversely, a bi-directional link between NCCR activity and
miRNA-expression appears biologically plausible, when signals of activating EVGR expression are
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sensed in the latently infected host cell, for example by displacing Sp1 from the SP1-4 binding site
in the LVGR promoter [30]. Downregulating the posttranscriptional miRNA then permits for an
efficient progression through the viral life cycle. In immunosuppressed patients lacking sufficient
CD8 T-cell activity, the high and prolonged viral replication allows for the emergence of rr-NCCR
variants conferring an activated EVGR expression and high-replication capacity [24], while reducing
posttranscriptional interference through BK-miRNA-5p downregulation
Given the potential clinical relevance for immunocompromised patients, we explored BKPyV
shedding, NCCR architecture and miRNA levels in multiple sclerosis patients treated with natalizumab.
We found that patients shedding BKPyV with rr-NCCRs had on average higher urine viral loads but
lower miRNA-5p levels in the exosome-enriched vesicles. Conversely, patients shedding BKPyV with
the archetype NCCR architecture showed lower viral loads and typically higher miRNA-5p levels in
urinary exosome preparations. Thus, these preliminary data, if confirmed, seem to be consistent in
their almost dichotomous nature and also provide an incentive for further work, which may be of
relevance for clinical diagnostic and therapeutic approaches [42,44].
Finally, there is increasing evidence reported that other viruses including those that have the
propensity to establish latent/persistent infections such as herpesviruses use miRNA regulation not
only intracellularly but also in exosomes [57]. Thus, besides a principle role in virus biology, our data,
together with those of other researchers, strongly suggest that viral miRNA should be explored further
in a virological and clinical context. To integrate our results into the work of other researchers and
to stimulate the corresponding projects, we present a model (see Figure 8) in which host cell signals,
viral NCCR activity and miRNA expression permit fine tuning of persistence, reactivation of replication,
spread to neighbouring host cells, for example, in the epithelial monolayer of the renal tubules and
hiding from cytotoxic large T-antigen-specific CD8 T-cells, unless the host is immunocompromised.
The potential role of exosomes and miRNA cargo in cell to cell communication offers an interesting
possibility that could potentially be harnessed for antiviral therapy.
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Figure 8. Model of BKPyV miRNAs expression and exosome traffic. (A) Immunocompetent host:1- 
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activation of EVGR expression and lowering of miRNA expression; 3- Exosomes deliver BKPyV miRNA 
cargo to uninfected cells; 4- Subsequent infection with archetype BKPyV counteract new rounds of viral 
replication, thereby avoid recognition by cytotoxic T-cells. (B) Immunocompromised host: 1- Status and 
consequences during BKPyV archetype persistent infection; 2- BKPyV with rearranged NCCR emerge in 
immunocompromised patients as the immune selection pressure fades; 3- No or low miRNA cargo in 
exosome delivery to uninfected neighbouring cells; 4- Rapid spread, increased cytopathology and 
functional failure. 
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